Eli Lilly Reports Improved One-Year Phase 3b Efficacy Data
Phase 3b data show improved one-year efficacy for Taltz and Zepbound in psoriatic arthritis and obesity.
Phase 3b data show improved one-year efficacy for Taltz and Zepbound in psoriatic arthritis and obesity.